Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PnCJ + PPS is a combination vaccine strategy that utilizes both a conjugated anti-pneumococcal vaccine (PnCJ) and a polysaccharide anti-pneumococcal vaccine (PPS). This "prime-boost" approach is designed to enhance immunogenicity compared to the use of the polysaccharide vaccine alone. The combination has been studied in patients with common variable immunodeficiency, aiming to improve immune response against Streptococcus pneumoniae by leveraging both T-cell dependent (conjugate) and T-cell independent (polysaccharide) mechanisms[1][2]. The developer involved in clinical studies is Institut National de la Santé Et de la Recherche Médicale, France.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PnCJ + PPS.